evipedia.ai
← Back

GHRP-6 for Health & Longevity

Evidence Review created on 11/05/2026 using AI4L / Opus 5.5

Also known as: Growth Hormone-Releasing Peptide-6, Growth Hormone-Releasing Hexapeptide, GHRP6, SKF-110679, CIGB-500

Motivation

GHRP-6 (growth hormone-releasing peptide-6) is a synthetic chain of six amino acids designed in the early 1980s to make the pituitary gland release the body’s own growth hormone. It acts on the same receptor as ghrelin, the stomach hormone that signals hunger, so one injection triggers a short pulse of growth hormone instead of supplying the hormone from outside.

Growth hormone output falls with age, and for more than a decade this peptide was studied in people both as a way to test pituitary function and as a way to stimulate hormone release. Separate laboratories later examined whether it protects tissue after injury. It has no approved medical use, and it reaches most users through unregulated suppliers.

This review examines what the evidence shows about GHRP-6 for health and longevity: how it acts, which effects have been measured in people and which have not, the hormonal and metabolic changes that accompany its use, the protocols described for it, and the problems of obtaining it.

Benefits - Risks - Protocol - Conclusion

High-level overviews of GHRP-6 and of the growth hormone secretagogue class (compounds that make the body release its own growth hormone) from expert and academic sources.

Content from Rhonda Patrick, Chris Kresser, Life Extension and Lifespan.io could not be included: Chris Kresser and Lifespan.io have nothing on GHRP-6; Life Extension names it only in passing, in articles on growth hormone replacement (Life Extension Magazine, June 1997) and on a conference session on secretagogues (Life Extension Magazine, May 1997), far short of the depth required here; and the one relevant FoundMyFitness item, a members-only question-and-answer session on growth hormone secretagogues, sits behind a paywall and so cannot be read or verified.

Grokipedia

  • GHRP-6

    A structured encyclopedia entry covering chemistry, receptor pharmacology, discovery history, investigational uses, bodybuilding use, adverse effects and legal status, useful mainly as an orientation map.

Examine

No Examine article exists for GHRP-6. Examine covers dietary supplements and does not typically cover prescription or unapproved injectable drugs such as GHRP-6, which is neither a supplement nor an approved medicine.

ConsumerLab

No ConsumerLab article exists for GHRP-6. ConsumerLab tests retail supplements and does not typically cover prescription or unapproved injectable drugs such as GHRP-6, which is not sold as a consumer supplement.

Systematic Reviews

No systematic reviews or meta-analyses for GHRP-6 were found on PubMed as of November 5, 2026.

The central trade-off of GHRP-6 — raising growth hormone output against weakening blood sugar control and raising stress hormones — is unrepresented on both sides: no systematic review or meta-analysis covers either the claimed effect or the principal risk for this compound. Reviews exist for the wider ghrelin-receptor agonist class (drugs that activate the ghrelin receptor), covering nutritional outcomes (Su 2016) and cancer risk (Sever 2016), but neither includes GHRP-6 trials, so neither is listed here.

Mechanism of Action

GHRP-6 activates the growth hormone secretagogue receptor 1a (GHS-R1a, the ghrelin receptor — the docking site for the stomach hunger hormone ghrelin), present in the pituitary gland and the hypothalamus (Howard 1996). The peptide predates that receptor’s discovery; ghrelin was identified in 1999 (Kojima 1999).

Blocking growth hormone-releasing hormone (GHRH, the brain’s signal for growth hormone release) removes most of the response (Pandya 1998), and it disappears entirely when the hypothalamus is disconnected from the pituitary (Popovic 1995) — placing the main site of action above the pituitary. Together, GHRP-6 and GHRH release far more growth hormone than either alone (Bowers 1990).

Two competing explanations of the surplus effect persist: opposition to somatostatin (the brake on growth hormone release), though atropine data show dependence on somatostatin tone rather than its lowering (Peñalva 1993), versus action through a still-unidentified hypothalamic factor (Bowers 1998). A second receptor, CD36 (a fat-transport receptor on heart and vessel cells), mediates this family’s cardiovascular actions, not growth hormone release (Bodart 2002).

It weighs 872 daltons. After intravenous dosing, distribution half-life is 7.6 ± 1.9 minutes and elimination half-life 2.5 ± 1.1 hours, measured by its developer, an interested party (Cabrales 2013); no human tissue-distribution data exist. Being a peptide, it is cleaved by peptidases (protein-cutting enzymes) rather than cytochrome P450 liver enzymes (the main drug-metabolising family), and much is excreted intact (Semenistaya 2015). Selectivity is partial: it also releases corticotropin (the pituitary signal driving cortisol), cortisol and prolactin (the lactation hormone).

Historical Context & Evolution

GHRP-6 was not derived from any natural hormone. It emerged from systematic modification of met-enkephalin fragments, and was reported in 1984 as a hexapeptide that released growth hormone in several species without moving luteinising hormone, follicle-stimulating hormone, thyroid-stimulating hormone or prolactin, and that increased weight gain in immature rats (Bowers 1984).

Its original intended use was therapeutic, as an alternative to injected growth hormone for deficiency states. The first human study, conducted by employees of Smith Kline & French Laboratories — the company developing it, an interested party — gave 0.05–2.5 µg/kg to 17 men and reported dose-dependent growth hormone release with no change in other pituitary hormones (Ilson 1989). Repeated nasal dosing then raised insulin-like growth factor 1 (IGF-1, the hormone through which growth hormone acts on tissue) (Hayashi 1991).

Interest in health optimisation followed from the observation that growth hormone secretion declines with age while the response to GHRP-6 held into the late fifties (Micic 1995), suggesting a functional, reversible decline. A review reports the response itself falling after the sixth decade (Ghigo 1997), so the width of that window was contested early.

Development then diverged rather than ended. The search for the receptor that GHRP-6 acts on led to its cloning and to ghrelin’s discovery, and industry moved to orally active non-peptides such as ibutamoren (Smith 2005). GHRP-6 itself survived in two niches: as a pituitary test (Popovic 2000) and in a Cuban tissue-protection programme. What changed was commercial attention, not a verdict on the molecule.

Expected Benefits

High 🟩 🟩 🟩

Provocation of Growth Hormone Release for Pituitary Testing ⭕️ Not Central to Health & Longevity

GHRP-6, alone or with GHRH, reliably provokes growth hormone release and correctly separates growth hormone-deficient adults from healthy ones against the insulin tolerance test, the clinical reference standard. Independent groups replicate this: the Belgrade–Santiago consortium of Popovic and Casanueva in 250 subjects (Popovic 2000) and Petersenn’s Hamburg group (Petersenn 2002). The threshold fails in severe obesity (Haijma 2005). This bears on diagnosis, not on health or lifespan.

Magnitude: Peak growth hormone 59.2 µg/L (SD 2.2; SD is the standard deviation, the spread of values around the average) in controls versus 4.1 µg/L (SD 0.3) in deficient adults after GHRH plus GHRP-6, against 14.3 versus 0.5 µg/L for the insulin tolerance test (Popovic 2000).

Medium 🟩 🟩

Increased Light Non-Dream Sleep

Repeated night-time injections increased stage 2 sleep, the largest phase of non-dream sleep, while leaving slow-wave (deep) sleep unchanged, in a randomised placebo-controlled crossover study in healthy men from the Max Planck Institute of Psychiatry (Frieboes 1995). Only this one group has measured sleep architecture with GHRP-6, which holds the grade at Medium. The same study found nocturnal corticotropin and cortisol rose, so the sleep change arrives together with a stress-hormone change rather than instead of one.

Magnitude: Stage 2 sleep 270.1 ± 25.3 minutes versus 245.4 ± 25.8 minutes on placebo (p < 0.02; p is the probability that a difference this large would arise by chance alone), a difference of about 25 minutes; slow-wave sleep unchanged (Frieboes 1995).

Low 🟩

Short-Term Rise in Insulin-Like Growth Factor 1 ⚠️ Conflicted

Seven nasal doses over two days raised IGF-1 in six men, with no placebo group (Hayashi 1991). Four days of oral dosing in seven elderly women did not raise it significantly, though the growth hormone response persisted (Ghigo 1994). Brief frequent dosing may lift IGF-1; short courses often do not.

Magnitude: IGF-1 94.5 ± 5.8 to 125.8 ± 6.0 µg/L after nasal dosing (no control group) (Hayashi 1991); 77.1 ± 8.4 to 84.1 ± 12.2 µg/L, not significant, after oral dosing (no control group) (Ghigo 1994).

Preservation of Fat-Free Mass in Older Adults

No GHRP-6 trial has measured body composition. The evidence is indirect: it comes from a different compound, the oral ghrelin mimetic ibutamoren, in a two-year randomised trial in 65 adults aged 60–81 (Nass 2008). Fat-free mass rose, but strength and physical function did not change, and fasting glucose rose.

Magnitude: Fat-free mass +1.1 kg (95% CI 0.7 to 1.5; CI is the confidence interval, the range within which the true value probably lies) versus −0.5 kg (95% CI −1.1 to 0.2) on placebo at 12 months (p < 0.001), a difference of about 1.6 kg (Nass 2008).

Neurological Recovery After Ischemic Stroke, Given With Epidermal Growth Factor ⚠️ Conflicted

Indirect: GHRP-6 was tested only with epidermal growth factor, never alone, and only by its developer. A phase I/II trial favoured the combination (Hernández-Bernal 2024), but its larger phase III trial missed the primary disability endpoint, with benefit only in a severe-stroke subgroup (Hernández-Bernal 2026). Net reading: unproven overall.

Magnitude: No difference in modified Rankin Scale (a disability score), Barthel index (a score of independence in daily activities) or survival overall; in severe stroke (n = 27), score 2.6 (95% CI 1.3–3.8) versus 4.7 (95% CI 2.6–6.0), p = 0.03 (Hernández-Bernal 2026).

Speculative 🟨

Protection of Heart Muscle After Ischemic or Toxic Injury

Animal only, from the developer: pre-treatment shrank dead heart muscle after artery blockage in pigs (Berlanga 2007) and prevented heart-chamber enlargement from doxorubicin, a chemotherapy drug, in rats (Berlanga-Acosta 2024). No human data exist.

Reduced Tissue Scarring and Multi-Organ Protection

Animal only. Rabbit scar prevention (Fernández-Mayola 2018) and rat protection against multi-organ failure (Cibrián 2006), both from the developing institute. The basis is mechanistic and animal work only.

Benefit-Modifying Factors

  • Visceral fat and baseline IGF-1: Abdominal visceral fat, IGF-1 and its binding protein together explained 60% of the variation in the growth hormone response to GHRH plus the related peptide GHRP-2 in 47 men (Veldhuis 2009).

  • Severe obesity: Response is blunted enough that the standard diagnostic threshold no longer applies in severely obese men (Haijma 2005), though GHRP-6 still outperforms GHRH in obesity (Cordido 1993).

  • Age: Response held between a young group and a group near 60 years, unlike the response to GHRH (Micic 1995). A review reports it falling after the sixth decade (Ghigo 1997); orally, people aged 66–85 responded non-significantly less than young adults (Ghigo 1994).

  • Sex and menstrual phase: No difference was found between men, women at different cycle stages, and prepubertal children (Peñalva 1993). Oestradiol instead shapes baseline, non-pulse growth hormone output (Veldhuis 2009).

  • Thyroid and adrenal conditions: Response is reduced in overactive thyroid (Nascif 2007) and in Cushing’s disease (a pituitary tumour driving excess cortisol), while it is preserved when the excess comes from medication (Borges 1997).

  • High blood sugar: A high-glucose clamp reduced the growth hormone response by roughly a quarter versus a normal-glucose clamp in men with type 2 diabetes (Micic 2004).

  • Circulating free fatty acids: Lowering free fatty acids with acipimox tripled the response to GHRH and raised the response to GHRH plus GHRP-6 in obese subjects (Cordido 1996).

  • Receptor gene variants: A missense variant (a single-letter DNA change that swaps one amino acid) in the gene for the ghrelin receptor impairs its baseline activity and tracks with short stature in two families, while leaving the response to stimulation intact (Pantel 2006).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Elevated Corticotropin and Cortisol

GHRP-6 is not selective for growth hormone: it also drives the stress-hormone axis, releasing corticotropin and cortisol. Independent groups show this — Bowers and Thorner at Tulane and Virginia (Bowers 1990), the Max Planck Institute group overnight (Frieboes 1995), Lengyel’s São Paulo group (Oliveira 2003) and Petersenn’s group in Essen, which saw significant stress-axis activation but limited diagnostic accuracy against the insulin tolerance test (Alaioubi 2010). More selective secretagogues avoid this, on data from the company developing one of them, an interested party (Raun 1998).

Magnitude: Overnight cortisol 56.0 ± 31.0 ng/mL versus 25.2 ± 9.0 ng/mL on placebo, a difference of about 31 ng/mL, and corticotropin 21.0 ± 5.3 versus 16.6 ± 3.1 pg/mL, a difference of about 4 pg/mL (both p < 0.02), in a randomised crossover (Frieboes 1995).

Medium 🟥 🟥

Elevated Prolactin

Prolactin, the pituitary hormone of lactation, rises with GHRP-6, apparently at the upper end of the dose range only. The data come from one research network: Bowers and Thorner in 18 healthy men given escalating intravenous doses (Bowers 1990), and Hayashi’s group in six men, with Bowers as co-author (Hayashi 1991), which holds the grade at Medium. No GHRP-6 study has followed prolactin long enough to show whether repeated use suppresses sex-hormone output.

Magnitude: Roughly a two-fold rise above each subject’s own baseline, and only at 1 µg/kg; not compared between groups, and no placebo-group prolactin figure is reported (Bowers 1990).

Low 🟥

Weakened Insulin Sensitivity and Higher Blood Glucose ⚠️ Conflicted

Regulators flag reduced insulin sensitivity for GHRP-6 (United States Food and Drug Administration category 2 list), and glucose and insulin rose sharply under growth hormone receptor blockade (Muller 2001). Yet single doses raised no glucose in two controlled studies (Nascif 2007, Borges 1997). Plausible with sustained use, unproven acutely.

Magnitude: Glucose 4.2 ± 0.3 to 6.0 ± 0.6 mmol/L and insulin 10.3 ± 2.1 to 81.3 ± 25.4 mU/L, within-group changes under receptor blockade, not compared between groups (Muller 2001).

Increased Appetite and Weight Gain

Indirect: the quantified human appetite data come from different compounds. GHRP-2 raised food intake in healthy men (Laferrère 2005), and ibutamoren raised body weight and appetite over a year (Nass 2008). For people managing body composition this is a drawback, not a benefit.

Magnitude: Food intake +35.9 ± 10.9% with GHRP-2, 136.0 ± 13.0 versus 101.3 ± 10.5 kJ/kg on saline (Laferrère 2005); body weight +2.7 kg (95% CI 2.0 to 3.5) versus +0.8 kg (95% CI −0.3 to 1.8) on placebo with ibutamoren, a difference of about 1.9 kg (p = 0.003) (Nass 2008).

Fluid Retention, Musculoskeletal Symptoms and a Heart Failure Signal

Indirect, from the class rather than GHRP-6: a year of ibutamoren produced transient lower-leg swelling and muscle pain (Nass 2008), and the FDA reports an ibutamoren hip-fracture trial stopped early over a congestive heart failure signal (United States Food and Drug Administration category 2 list). Both follow raised growth hormone.

Magnitude: Mild, transient edema in 19/43 (44%) on ibutamoren versus 6/22 (27%) on placebo (p = 0.3), and muscle pain in 14/43 (33%) versus 2/22 (9%) (p = 0.1); no event rate for heart failure is given in the FDA source (Nass 2008).

Transient Facial Flushing ⚠️ Conflicted

Brief warmth and reddening of the face after injection, from the peptide’s effect on small blood vessels. It was the only adverse event in one study of 20 patients (Petersenn 2002), while a 250-subject multicentre study of the test reported none (Popovic 2000). Net reading: uncommon and self-limiting.

Magnitude: Not quantified in available studies. Neither study reports an event rate, and neither carried a placebo arm against which flushing could be counted.

Impure, Mislabelled or Immunogenic Product

United States regulators placed GHRP-6 in category 2 for outsourcing facilities in September 2023, citing immunogenicity (an immune reaction against the injected peptide) from aggregation and impurities (United States Food and Drug Administration category 2 list). Analysis of black-market products found GHRP-6 variants not matching their labels (Krug 2018).

Magnitude: Not quantified in available studies. No controlled study has measured antibody formation or injury rates from GHRP-6 products; the evidence is regulatory assessment plus analytical findings on seized or purchased material.

Speculative 🟨

Promotion of Existing Tumour Growth ⚠️ Conflicted

Mechanistic concern: growth hormone and IGF-1 promote cell division; no human outcome data exist. A systematic review found 45 of 61 studies, including all eleven treatment studies, null or inverse (Sever 2016). It is unsupported.

Coronary Vessel Narrowing Through CD36

Animal and isolated-tissue only. A related peptide of this family raised coronary perfusion pressure through CD36 in perfused rat hearts, an effect absent in CD36-deficient animals (Bodart 2002). No human vascular data exist.

Risk-Modifying Factors

  • Existing insulin resistance or prediabetes: Growth hormone opposes insulin’s action, so anyone whose glucose control is already marginal has less reserve; a year of a related secretagogue raised fasting glucose and lowered insulin sensitivity (Nass 2008).

  • Baseline IGF-1 near or above the reference ceiling: A high starting IGF-1 leaves little headroom before dosing pushes it out of range, and higher baseline IGF-1 predicted a larger response to GHRH plus GHRP-2 (Veldhuis 2009).

  • Disorders of the stress-hormone axis: GHRP-6 raises corticotropin and cortisol even in Cushing’s disease, where output is already excessive (Oliveira 2003), compounding the hormonal problem rather than revealing it.

  • Sex: No sex difference has been found in the growth hormone response (Peñalva 1993), and no study has reported sex-specific side-effect rates for GHRP-6. Whether the prolactin effect differs between men and women is untested.

  • Age: Adults near 60 keep a full growth hormone response (Micic 1995), which a review reports declining beyond that age (Ghigo 1997), while background glucose intolerance and undetected tumours rise, so the same dose meets a less tolerant background.

  • Receptor gene variants: No polymorphism has been linked to GHRP-6 side effects. The ghrelin-receptor variant that lowers baseline receptor activity leaves the response to stimulation intact (Pantel 2006), so it predicts no different risk.

  • Concurrent glucocorticoid medication: A single dose of dexamethasone roughly doubled the growth hormone response to GHRP-6 (Pinto 1999), so steroid courses can amplify effects unpredictably.

Key Interactions & Contraindications

Documented interactions:

  • GHRH analogues (sermorelin, tesamorelin, CJC-1295): Synergistic growth hormone discharge far exceeding the sum of each alone (Bowers 1990). Consequence: unpredictably large hormonal exposure. Mitigation: a reduced GHRP-6 dose, or separation of the agents.

  • Anticholinergic drugs (atropine, scopolamine, oxybutynin — they block the nerve signal acetylcholine): Atropine completely prevented the growth hormone response (Peñalva 1993). Consequence: loss of effect. Mitigation: dosing separated by several hours.

  • Cholinesterase inhibitors (pyridostigmine, donepezil — they raise acetylcholine levels): Pyridostigmine doubled the growth hormone response in obese subjects (Cordido 1993). Consequence: amplified hormonal effect, including its glucose and cortisol components. Mitigation: a lower GHRP-6 dose.

  • Glucocorticoids (dexamethasone, prednisone — synthetic versions of cortisol): A single dexamethasone dose roughly doubled the growth hormone response (Pinto 1999), while chronic internal cortisol excess blunts it (Borges 1997). Consequence: unpredictable response during steroid courses.

  • Insulin and glucose-lowering agents (insulin, glipizide, gliclazide): Insulin-induced hypoglycaemia markedly increased the growth hormone response (Peñalva 1993), and high glucose blunted it (Micic 2004). Consequence: response varies with glycaemic state. Mitigation: fasted dosing with glucose monitoring.

  • Growth hormone receptor antagonists (pegvisomant): Under blockade, GHRP-6 produced a sharp rise in insulin and glucose (Muller 2001). Consequence: acute insulin resistance. Avoid — the pairing has no therapeutic rationale.

  • Lipid-lowering agent acipimox: Lowering free fatty acids amplified the response to GHRH plus GHRP-6 (Cordido 1996). Consequence: a larger hormonal pulse than expected from the dose.

  • Alpha-2 and beta-adrenergic agents (clonidine, propranolol — they damp adrenaline signalling): No interaction found — neither altered the growth hormone response to GHRP-6 in healthy men (Peñalva 1993). The alpha-1 blocker (a blood pressure drug that relaxes vessels) prazosin did increase it.

  • Antifungal ketoconazole: Cortisol responses to GHRP-6 fell after three and six months of treatment in Cushing’s disease, while the corticotropin rise did not change significantly (Correa-Silva 2010). Consequence: an altered response during prolonged antifungal therapy.

  • Arginine supplements: Oral arginine nearly doubled the growth hormone response to oral GHRP-6 in people aged 66–85, while leaving it unchanged in young adults (Ghigo 1994). Consequence: a larger hormonal pulse in older users.

  • Somatostatin and its analogues (octreotide, lanreotide): Exogenous somatostatin blunts the growth hormone response to growth hormone-releasing peptides in humans, as a review reports (Ghigo 1997). Consequence: a blunted growth hormone response — loss of effect rather than harm.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Other ghrelin-receptor agonists (ipamorelin, hexarelin, ibutamoren): Inferred from shared GHS-R1a activation. Consequence: additive hormonal effects and faster receptor desensitisation, which single-agent use avoids.

  • Agents that raise prolactin (risperidone, haloperidol, metoclopramide): Inferred from GHRP-6’s own prolactin-releasing effect. Consequence: additive prolactin elevation, with possible suppression of sex-hormone output. Mitigation: prolactin measurement.

  • Over-the-counter anticholinergic antihistamines (diphenhydramine, dimenhydrinate): Inferred from the loss of response under atropine. Consequence: a blunted growth hormone pulse when they are taken close to dosing, which separation by several hours avoids.

  • Thyroid hormone replacement (levothyroxine, liothyronine): Inferred from the reduced response seen in thyroid hormone excess. Consequence: a smaller growth hormone pulse if replacement is over-dosed. Mitigation: confirmation that thyroid status is in range.

Populations who should avoid GHRP-6:

  • People with acromegaly (growth hormone excess, usually from a pituitary tumour): GHRP-6 raised growth hormone in 10 of 11 patients with active acromegaly, and did so synergistically with GHRH (Hanew 1994) — adding to an already pathological excess.

  • People with corticotropin-dependent Cushing’s disease or any cause of cortisol excess: GHRP-6 raised corticotropin and cortisol in these patients as strongly as a standard provocation agent (Oliveira 2003), worsening the underlying disorder.

  • People with active or recently treated cancer: Inferred from the cell-division-promoting action of growth hormone and IGF-1; no human data show harm, and a systematic review of ghrelin agonists found no excess risk (Sever 2016).

  • People with uncontrolled diabetes: Inferred from growth hormone’s opposition to insulin action and the regulator’s stated insulin-sensitivity concern (United States Food and Drug Administration category 2 list); no human study has dosed this group.

  • People with active proliferative diabetic retinopathy (diabetic eye damage with abnormal new blood vessels in the retina): Inferred from the role of IGF-1 in retinal blood-vessel growth; no human data on GHRP-6 in this group exist.

  • Pregnant and breastfeeding women: Inferred from the complete absence of reproductive and developmental data in humans, together with the hormonal breadth of the compound; no human study has included pregnancy.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Pre-treatment metabolic screen: Fasting glucose, fasting insulin and IGF-1 measured before starting detect the insulin resistance that growth hormone exposure can worsen (Nass 2008).

  • Intermittent rather than continuous dosing: Spacing doses limits the receptor desensitisation that continuous infusion produces, as a review reports (Ghigo 1997), preserving the response and avoiding unnecessary sustained exposure.

  • Lowest effective dose: Prolactin and cortisol rose only at 1 µg/kg, the top tested intravenous dose (Bowers 1990), yet repeated 50 µg boluses still raised cortisol (Frieboes 1995), so lower doses limit rather than remove off-target hormonal release.

  • Stopping on a rising glucose signal: Fasting glucose ≥126 mg/dL or glycated haemoglobin ≥6.5% is the stopping threshold, per diagnostic cutoffs from a body whose members treat diabetes (American Diabetes Association Standards of Care 2026).

  • Independent identity and purity testing: A batch mass-spectrometry certificate guards against the mislabelled GHRP-6 variants found in black-market growth-promoting products (Krug 2018).

  • Oncological clearance before use: Growth hormone and IGF-1 promote cell division, so age-appropriate cancer screening before starting addresses the theoretical tumour-growth concern that GHRP-6 cannot yet exclude.

  • No stacking with other secretagogues: Combining GHRP-6 with GHRH analogues multiplies growth hormone output far beyond either alone (Bowers 1990), which amplifies the glucose and cortisol effects alongside it.

Therapeutic Protocol

No approved regimen exists for GHRP-6, which carries no regulatory approval for performance use, as a review records (Dominikowski 2026). Each dose below is cited to its source; other parameters without a citation, including timing, cycling and titration steps, reflect common practice.

  • Diagnostic regimen: 1 µg/kg intravenously, alone or with GHRH 1 µg/kg, with growth hormone sampled over 90–120 minutes — the best-validated use, developed by Popovic and Casanueva (Popovic 2000).

  • Tissue-protection regimen: 3.5 mg or 5 mg intravenously twice daily for seven days, with epidermal growth factor, in the Cuban stroke trials run by the institute that developed the product (Hernández-Bernal 2024).

  • Self-administration regimen: 100–300 µg subcutaneously or intramuscularly, two or three times daily and fasted, in cycles of 8–12 weeks — the protocol circulating in unregulated channels, catalogued but not endorsed in a published review (Dominikowski 2026).

  • Competing approaches: Practitioners pair GHRP-6 with a GHRH analogue, or use GHRH analogues alone; the published human dose is 1 µg/kg intravenously (Bowers 1990) against 100–300 µg subcutaneously in circulating protocols (Dominikowski 2026).

  • Best time of day: Bedtime dosing aligns the pulse with nocturnal growth hormone release; the one sleep study dosed overnight (Frieboes 1995). Morning dosing suits those who find sleep disturbed.

  • Half-life: Distribution half-life 7.6 minutes, elimination half-life 2.5 hours (Cabrales 2013) — short enough that the hormonal effect is a pulse, not steady coverage.

  • Single versus split dosing: The short half-life makes each injection a discrete pulse, so split dosing produces multiple pulses rather than sustained levels; continuous delivery instead causes desensitisation, per a review (Ghigo 1997).

  • Route alternatives: Oral 300 µg/kg and nasal 5–30 µg/kg both release growth hormone, at far higher doses than injection (Bellone 1995, Hayashi 1991).

  • Genetic variants: A variant in the ghrelin receptor gene reduces its baseline activity but preserves the response to stimulation (Pantel 2006); no pharmacogenetic test guides dosing.

  • Sex differences: No dose adjustment is supported — response did not differ by sex or menstrual phase (Peñalva 1993). Oestradiol status affects baseline growth hormone output rather than the pulse (Veldhuis 2009).

  • Age considerations: Response is preserved into the late fifties (Micic 1995) but declines beyond it, per a review (Ghigo 1997); oral arginine augmented the oral response in people aged 66–85 (Ghigo 1994).

  • Baseline biomarkers: Visceral fat, IGF-1 and its binding protein explained 60% of the variation in response to GHRH plus GHRP-2 (Veldhuis 2009); leaner men with higher IGF-1 responded more strongly.

  • Pre-existing conditions: Overactive thyroid and Cushing’s disease blunt the response (Nascif 2007, Borges 1997); in type 2 diabetes, high blood glucose blunts it (Micic 2004).

Discontinuation & Cycling

  • Lifelong or short-term: All human use has been short-term — single diagnostic doses, days of repeated dosing, or a seven-day course (Hernández-Bernal 2024). No study has run beyond that, so no basis exists for continuous use.

  • Withdrawal effects: None documented. GHRP-6 prompts the pituitary rather than replacing its output, so the suppression that follows injected growth hormone is not expected; no study has looked for rebound after stopping.

  • Tapering: No taper protocol exists or appears necessary given the 2.5-hour elimination half-life (Cabrales 2013), which leaves no accumulated drug to withdraw from.

  • Cycling to maintain effect: Partly supported. A review reports more desensitisation under continuous infusion than under intermittent dosing (Ghigo 1997), which argues for breaks; four days of oral dosing showed no loss of effect (Ghigo 1994).

Sourcing and Quality

  • No legitimate supply channel: GHRP-6 is neither an approved medicine nor a dietary supplement. United States drug regulators placed it in category 2 for outsourcing facilities in September 2023 (United States Food and Drug Administration category 2 list), so compounding it there is not sanctioned.

  • Research-chemical market: Material is sold as lyophilised (freeze-dried) powder “for research use only”, outside pharmaceutical quality systems. Analysis of such products found modified variants including a glycine-extended GHRP-6 not matching any label (Krug 2018).

  • What to look for: A batch-specific certificate of analysis from an independent laboratory using mass spectrometry and high-performance liquid chromatography, reporting peptide identity, purity above 98%, water content, and sterility and endotoxin results for injectable use.

  • Aggregation as the specific hazard: The regulator’s stated concern is immunogenicity from aggregation and peptide-related impurities (United States Food and Drug Administration category 2 list), so handling matters: heat and agitation promote aggregation, and visible cloudiness or particles indicate a degraded product.

  • Named products: CIGB-500 is an investigational GHRP-6 product from Cuba’s Center for Genetic Engineering and Biotechnology, which developed it and has a commercial interest in it; its published data include a 28-day dog safety study (Castro 2025). No regulatory approval was found.

  • Reconstitution and storage: Powder is stable refrigerated; once reconstituted with bacteriostatic water, practitioners keep it refrigerated and use it within weeks. No stability data for reconstituted GHRP-6 have been published.

Practical Considerations

  • Time to effect: Hormonal effects are immediate — growth hormone peaked at 45 minutes after a 30-minute infusion (Ilson 1989). IGF-1 shifts need days of repeated dosing, and body-composition change has never been demonstrated for GHRP-6 at all.

  • Common pitfalls: High blood glucose or high circulating free fatty acids blunt the response (Micic 2004, Cordido 1996), though a standard lunch did not (Popovic 2002); continuous rather than pulsed dosing desensitises it, per a review (Ghigo 1997).

  • Mistaking it for a selective compound: GHRP-6 is among the least selective secretagogues, adding cortisol, corticotropin, prolactin and hunger to the growth hormone pulse; ipamorelin, by contrast, unexpectedly spared cortisol and corticotropin in animal testing (Raun 1998).

  • Regulatory status: Listed only as a bulk substance for compounding, in category 2 for outsourcing facilities (United States Food and Drug Administration category 2 list); a review records no regulatory approval for performance use (Dominikowski 2026). No label, so no off-label pathway.

  • Competition prohibition: Growth hormone-releasing peptides including GHRP-6 sit in section S2 of the World Anti-Doping Agency’s list, prohibited at all times (WADA Prohibited List). Urine detection persists about a day after dosing (Semenistaya 2015).

  • Cost and access: Inexpensive as a research chemical, but with no oversight and no recourse if vial contents differ from the label. Insurers fund costly growth hormone only for approved uses, so a cheap unapproved alternative attracts no payer advocacy, research funding or guideline attention.

Interaction with Foundational Habits

  • Sleep: Direct and two-directional. Night-time dosing increased stage 2 sleep but also raised overnight cortisol, a hormone that normally falls during early sleep (Frieboes 1995). Practitioners place dosing at bedtime to coincide with natural growth hormone release, and report that the hunger it provokes can itself disturb sleep.

  • Nutrition: Blunting, through fuel availability. High circulating free fatty acids suppress the growth hormone response, and lowering them with acipimox amplified it (Cordido 1996); high blood glucose blunts it (Micic 2004). Practitioners therefore avoid carbohydrate for about 45 minutes to two hours before dosing. Oral arginine augmented the oral response in older adults (Ghigo 1994).

  • Exercise: Additive, through separate pathways. Combining GHRP-6 with cycling near the lactate threshold (the effort above which lactate builds up in the blood) raised growth hormone pulse frequency and amplitude beyond either alone, and the study concluded exercise works through GHRH, not a GHRP-like signal (Nooitgedagt 1997). No blunting of training adaptation has been reported.

  • Stress management: Potentiating, and unwanted. GHRP-6 activates the same corticotropin–cortisol axis that stress activates (Frieboes 1995), so it adds to an existing cortisol load rather than being neutral to it. A single dose of dexamethasone also doubled the growth hormone response (Pinto 1999), indicating a two-way link.

Monitoring Protocol & Defining Success

A hormonal and metabolic baseline precedes use, because almost every measurable effect of GHRP-6 is a hormone shift and the compound’s main documented hazards are metabolic. Baseline testing covers IGF-1, fasting glucose, glycated haemoglobin, fasting insulin, morning cortisol and prolactin, drawn fasting and in the morning. The metabolic and hormonal panel is then repeated at about four weeks, when any sustained shift in glucose handling or prolactin becomes apparent, every three to six months during continued use, and at any point when appetite, swelling or sleep changes markedly. Success is defined narrowly, because the evidence supports little: IGF-1 moving upward while remaining inside its age- and sex-specific reference interval, with glucose, cortisol and prolactin unchanged. A rise in glucose or prolactin counts as a failed trade, not an acceptable cost.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Insulin-like growth factor 1 (IGF-1) Age- and sex-specific laboratory reference interval (standard reference range) Marker the intervention is expected to change; the main readable consequence of raised growth hormone Fasting not required. Interpretation is against the individual’s own baseline; repeated dosing raised it in one uncontrolled study and not in another (Hayashi 1991, Ghigo 1994)
Fasting plasma glucose 70–99 mg/dL (3.9–5.5 mmol/L) (standard reference range) Safety check; a rise is grounds to stop, since growth hormone opposes insulin’s action An 8-hour fast is required, and fasting insulin is best drawn alongside. 126 mg/dL is a diagnostic cutoff, not a target, set by a professional body whose members treat diabetes (American Diabetes Association Standards of Care 2026)
Glycated haemoglobin 4.0–5.6% (standard reference range) Safety check; detects sustained glucose drift that single fasting readings miss Glycated haemoglobin (HbA1c) is average blood sugar over about three months. 5.7% and 6.5% are diagnostic cutoffs, not functional targets, set by a professional body whose members treat diabetes (American Diabetes Association Standards of Care 2026)
Fasting insulin About 2.6–24.9 mU/L, laboratory-specific (standard reference range) Safety check; rises before glucose does when insulin sensitivity falls Drawn fasting, together with glucose. Insulin rose 8-fold under growth hormone receptor blockade (Muller 2001)
Morning serum cortisol 5–25 µg/dL (138–690 nmol/L) (standard reference range) Safety check; GHRP-6 directly stimulates the stress-hormone axis Drawn between 07:00 and 09:00, since cortisol follows a daily rhythm. Overnight cortisol doubled with night-time dosing (Frieboes 1995)
Prolactin Men 4–15 ng/mL; women 4–23 ng/mL (standard reference range) Marker the intervention is expected to change; sustained elevation suppresses sex-hormone output Drawn mid-morning, away from stress and recent breast stimulation, both of which raise it. Rose about two-fold at the top dose (Bowers 1990)

Qualitative markers worth tracking alongside the laboratory panel:

  • Appetite and hunger intensity, particularly in the hours after dosing
  • Sleep quality, time to fall asleep, and night-time awakenings
  • Swelling of hands, ankles or feet, including tightness of rings and shoes
  • Joint and muscle discomfort, and numbness or tingling in the hands
  • Injection-site redness, pain or lumps, which may signal product impurity

Emerging Research

  • No registered GHRP-6 trial: ClinicalTrials.gov holds no interventional study of GHRP-6 as of November 2026. All recent human work has been registered in Cuba’s national registry (Cuban Registry of Clinical Trials), so the public record of this compound sits largely outside the main trial databases.

  • COURAGE-2 completed, results published: The phase III trial of GHRP-6 with epidermal growth factor in acute ischemic stroke completed and reported in 2026, missing its primary disability endpoint (Hernández-Bernal 2026). A confirmatory severe-stroke trial would strengthen the combination’s case; a second null result would end it.

  • GHRP-3 trial withdrawn: A phase I/II study of continuous GHRP-3 infusion on insulin resistance and endothelial function in older adults was withdrawn for inadequate recruitment, with no participants enrolled and no results (NCT00846872). It was the closest thing to a longevity-relevant secretagogue trial.

  • Oral ghrelin agonist in heart failure: GOAL-HF2 tests the oral ghrelin receptor agonist AC01 against placebo in 400 patients with heart failure with reduced ejection fraction (a weakened heart pump) over 12 weeks, completing August 2028 (NCT07584967). A positive cardiac-structure result would support the receptor as a cardioprotective target; a null one would weaken it.

  • Oral secretagogue in growth hormone deficiency: A phase III placebo-controlled trial of daily oral LUM-201 (ibutamoren mesylate) in 150 children with growth hormone deficiency completes in January 2028 (NCT06948214). Success would show an oral secretagogue producing a clinical effect; failure would favour direct hormone replacement.

  • Secretagogue effects on physical function: Tesamorelin with exercise in 100 people with HIV (human immunodeficiency virus)-associated frailty completes December 2028 (NCT06554717). A positive result would show secretagogue-driven lean mass translating into function; a null one would confirm the gap left when a year of ibutamoren raised lean mass without improving strength (Nass 2008).

  • The opposite hypothesis: Work on reduced growth hormone signalling and longevity cuts against this intervention class. Long-lived dwarf mice (Brown-Borg 1996) and people with growth hormone receptor deficiency, who showed almost no cancer or diabetes (Guevara-Aguirre 2011), suggest less signalling, not more, may favour lifespan.

  • Unresolved mechanism: Whether the surplus effect of this peptide family runs through a still-unidentified hypothalamic factor remains open (Bowers 1998), as does the clinical significance of the separate CD36 pathway in human vessels (Bodart 2002).

Conclusion

GHRP-6 is a small synthetic peptide that makes the pituitary gland release a pulse of the body’s own growth hormone by acting on the receptor for the hunger hormone ghrelin. Its hormonal effect is beyond dispute and has been reproduced for nearly forty years across many independent laboratories. What has never been shown is that this translates into any benefit for health or lifespan. The strongest human evidence supports only its use as a pituitary test. One small study found modestly more light sleep. Everything else rests on short uncontrolled courses, on different compounds in the same family, on animal work, or on a combination treatment whose large trial did not meet its main goal.

Against this sit effects that are better documented than the benefits: the peptide also releases stress and lactation hormones, stimulates appetite, and is flagged by regulators for weakening blood sugar control. Much of the tissue-protection literature comes from the single institute that developed the product, an interest worth weighing. Because no approved version exists, material reaches users through unregulated suppliers where mislabelled variants have been found.

The evidence base is therefore wide but shallow: abundant short-term hormonal data, almost no outcome data, and no long-term safety record. For anyone optimising health over decades, that asymmetry — well-characterised costs against unmeasured benefits — is the central finding.

Top - Benefits - Risks - Protocol